Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(13):963-965; doi:10.1093/jnci/93.13.963
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Swain, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swain, S. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 13, 963-965, July 4, 2001
© 2001 Oxford University Press

EDITORIAL

Tamoxifen and Contralateral Breast Cancer: the Other Side

Sandra M. Swain

Affiliation of author: Medicine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

Correspondence to: Sandra M. Swain, M.D., National Institutes of Health, 10 Center Dr., Bldg. 10, Rm. 12N226, MSC 1906, Bethesda, MD 20892-1906 (e-mail: Swains@mail.nih.gov).

Tamoxifen has been administered to thousands of women during the last 30 years. Initially, it was used for treatment of metastatic breast cancer, next for adjuvant treatment of breast cancer, and most recently for reduction in the incidence of breast cancer in high-risk women. Tamoxifen is one of the first molecularly targeted therapies to be successful in improving survival in a large number of patients with a common cancer. It is thought that tamoxifen functions as an antiestrogen by structurally altering the estrogen receptor (ER), which thereby disrupts the ER–estradiol complex (1). An overview of randomized trials of adjuvant hormonal therapy with tamoxifen included information on 37 000 women, of whom 18 000 were ER positive and 12 000 had unknown ER status (2). This overview showed that the 10-year survival of women who had ER-positive tumors was increased substantially by tamoxifen treatment. The absolute increase . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
S. M. Swain, J. W. Wilson, E. P. Mamounas, J. Bryant, D. L. Wickerham, B. Fisher, S. Paik, and N. Wolmark
Estrogen Receptor Status of Primary Breast Cancer Is Predictive of Estrogen Receptor Status of Contralateral Breast Cancer
J Natl Cancer Inst, April 7, 2004; 96(7): 516 - 523.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. G. Vogel
Why Do We Still Use Hormone Replacement Therapy? Why Don't We Use It More?
J. Clin. Oncol., February 1, 2002; 20(3): 616 - 619.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. I. Li, K. E. Malone, N. S. Weiss, and J. R. Daling
Re: Tamoxifen and Contralateral Breast Cancer: the Other Side
J Natl Cancer Inst, November 21, 2001; 93(22): 1753 - 1753.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. W. Lee, L. Weir, and K. A. Gelmon
Effect of News Media Coverage of Cancer Risk on Clinical Oncology Practice
J Natl Cancer Inst, November 7, 2001; 93(21): 1656 - 1657.
[Full Text] [PDF]